Floatz logo

Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-24*01 (84.5%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-1*01 (88.1%) -Igkj4*01 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa

Cutaneous Melanoma

Explore 142 assets in Cutaneous Melanoma →
Floatz Rating
CC45/100
Confidence
Indicative
v0.2
Sponsor
Aulos Bioscience, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05267626CT.gov
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Cutaneous Melanoma

AssetSponsorPhaseRating
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-24*01 (84.5%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-1*01 (88.1%) -Igkj4*01 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa (this asset)Aulos Bioscience, Inc.P1/2CC · 45
Alpha-InterferonMIPO ClinicP3BBB
DacarbazineLinnaeus Therapeutics, Inc.P3BBB
Cis-Diamminedichloroplatinum IiMIPO ClinicP3BBB
TILCity of Hope Medical CenterP2BBB
Tyrosinase PeptideUniversity of Southern CaliforniaP3BBB
Multi-Epitope Melanoma Peptide VaccineCraig L Slingluff, JrP2BB
NivestimVastra Gotaland RegionP3BB
CediranibJonsson Comprehensive Cancer CenterP3BB

+42 more in the Cutaneous Melanoma cohort

Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-24*01 (84.5%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-1*01 (88.1%) -Igkj4*01 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa

IndicationSponsorPhaseRating
Metastatic Malignant Neoplasm—P1/2CC · 43
Cancer—P1/2CC · 40
Non-Small Cell Lung Carcinoma—P1/2CC · 40

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-24*01 (84.5%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-1*01 (88.1%) -Igkj4*01 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa in Cutaneous Melanoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-il2-interleukin-2-homo-sapiens-antibody-gamma1-heavy-chain-homo-sapiens-1-451-vh-homo-sapiens-ighv1-2401-845-ighd-ighj401-929-cdr-imgt-8814-26-3351-5897-110-1-121-homo-sapiens-ighg101-g1m171-g1v43-ch2-a13-e12-a1-ch1-k120-218-122-219-hinge-1-15-220-234-ch2-l13a-238-l12e-239-235-344-ch3-345-449-chs-450-451-122-451-224-220-disulfide-with-kappa-light-chain-homo-sapiens-1-220-v-kappa-homo-sapiens-igkv4-101-881-igkj401-909-cdr-imgt-1239-27-3856-5895-103-1-113-homo-sapiens-igkc01-100-km3-a451-159-v101-197-114-220-dimer230-230233-233-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-derived-from-the-cell-line-cho-k1-glycoform-alfa-cutaneous-melanoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →